A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT02852967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Study identification
- NCT ID
- NCT02852967
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2016 (Actual)
- Primary completion
- Feb 13, 2019 (Actual)
- Completion
- Feb 13, 2019 (Actual)
- Last update posted
- Mar 16, 2022
2016 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance Dermatology and Mohs Center | Phoenix | Arizona | 85032 | — |
| University of California, Irvine - Dermatology Clinical Research Center | Irvine | California | 92697 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Renstar Medical Research | Ocala | Florida | 34471 | — |
| Dawes Fretzin Dermatology Group | Indianapolis | Indiana | 46256 | — |
| Dermatology Specialists Research | New Albany | Indiana | 40202 | — |
| Dermatology Specialists Research | Louisville | Kentucky | 40202 | — |
| Metro Boston Clinical Partners | Brighton | Massachusetts | 02135 | — |
| Psoriasis Treatment Center of Central New Jersey | East Windsor | New Jersey | 08520 | — |
| Sadick Research Group | New York | New York | 10075 | — |
| Oregon Dermatology and Research Center | Portland | Oregon | 97210 | — |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37215 | — |
| Suzanne Bruce and Associates | Katy | Texas | 77056 | — |
| Austin Institute for Clinical Research | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02852967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2022 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02852967 live on ClinicalTrials.gov.